Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Daniel D. De Carvalho"'
Autor:
Pearson AD; Accelerate, UK. Electronic address: andy1pearson@btinternet.com., Stegmaier K; Dana-Faber Cancer Institute/Harvard Medical School, USA., Bourdeaut F; Institute Curie, France., Reaman G; US Food and Drug Administration, USA., Heenen D; KickCancer Foundation, Belgium., Meyers ML; Syndax Pharmaceuticals Inc, USA., Armstrong SA; Dana-Faber Cancer Institute/Harvard Medical School, USA., Brown P; Johns Hopkins Hospital, USA., De Carvalho D; University Health Network, Canada., Jabado N; McGill University Health Centre, Canada., Marshall L; Royal Marsden NHS Foundation Trust/Institute of Cancer Research, UK., Rivera M; Massachusetts General Hospital, USA., Smith M; National Cancer Institute, USA., Adamson PC; Sanofi US, Emeritus Professor of Paediatrics and Pharmacology, Perelman School of Medicine, University of Pennsylvania, USA., Barone A; US Food and Drug Administration, USA., Baumann C; GlaxoSmithKline, USA., Blackman S; Day on Therapeutics Inc, USA., Buenger V; Coalition Against Childhood Cancer, USA., Donoghue M; US Food and Drug Administration, USA., Duncan AD; Salarius Pharma, USA., Fox E; St Jude Children's Research Hospital, USA., Gadbaw B; Novartis Pharmaceuticals Corp, USA., Hattersley M; AstraZeneca, USA., Ho P; Boston Pharmaceuticals, USA., Jacobs I; Pfizer, USA., Kelly MJ; Syros Pharmaceuticals, USA., Kieran M; Bristol Myers Squibb, USA., Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands., Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands., Ludwinski D; Solving Kids' Cancer, USA., McDonough J; The Andrew McDonough B+ Foundation, USA., Nikolova Z; Celgene, Switzerland., Norga K; Antwerp University Hospital, Paediatric Committee of the European Medicines Agency, Federal Agency for Medicines and Health Products, Belgium., Senderowicz A; Constellation Pharma, USA., Taube T; Boehringer Ingelheim, Germany., Weiner S; Children's Cancer Cause, USA., Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency (EMA), Amsterdam, Netherlands., Vassal G; Gustave Roussy Cancer Centre, France.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Nov; Vol. 139, pp. 135-148. Date of Electronic Publication: 2020 Sep 26.
Autor:
Shengrui Feng, Daniel D. De Carvalho
Publikováno v:
The FEBS Journal. 289:1214-1239
The appropriate coordination between epigenetic regulators is essential for spatial and temporal regulation of gene expression and maintenance of cell identity. Cancer is a disease driven by both genetic and epigenetic alterations. The widespread dys
Autor:
Wail Ba-alawi, Evelyne Lima-Fernandes, Jason W. Locasale, Daniel D. De Carvalho, Paul Savage, Ilias Ettayebi, Hellen Kuasne, Morag Park, Felicia Tai, Yunchi Ingrid Kao, Benjamin Haibe-Kains, Alexandra N. Fedor, Paul Guilhamon, Giacomo Grillo, Seyed Ali Madani Tonekaboni, Cheryl H. Arrowsmith, Xiaojing Liu, Constanza Martinez, Anne-Marie Fortier, Mathieu Lupien, Alex Murison, Geneviève Deblois, David W. Cescon
Publikováno v:
Cancer Discovery. 10:1312-1329
Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant
Autor:
Bharati Bapat, Ruth Isserlin, Gary D. Bader, Misha Bilenky, Aaron R. Hansen, Pingzhao Hu, Neil E. Fleshner, Daniel D. De Carvalho, Anthony M. Joshua, Martin Hirst, Shu Yi Shen, Madonna R. Peter
AimWe examined methylation changes in cell-free DNA (cfDNA) in metastatic castration resistant prostate cancer (mCRPC) during treatment.Materials and MethodsGenome-wide methylation analysis of sequentially collected cfDNA samples derived from mCRPC p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223314f83e2907bd205f2d3042b62e66
https://doi.org/10.1101/2020.04.08.032565
https://doi.org/10.1101/2020.04.08.032565
Autor:
Daniel D. De Carvalho, Helen Loo Yau
Publikováno v:
STAR Protocols, Vol 2, Iss 2, Pp 100549-(2021)
STAR Protocols
STAR Protocols
Summary CD8+ T cells are key effector cells in adaptive immune responses against intracellular pathogens and cancer cells. Systemic drug treatments, like chemotherapy, may positively or negatively affect CD8+ T cell function. In this protocol, we des
Publikováno v:
Pharmacologytherapeutics. 205
DNA methylation patterns are frequently altered in cancer cells as compared to normal cells. A large body of research associates these DNA methylation aberrations with cancer initiation and progression. Moreover, cancer cells seem to depend upon thes
Autor:
Gareth E. Jones, Katia B Pagnano, Fabíola Attié de Castro, Beatriz F Ribeiro, Nelson Hamerschlak, Luiz Roberto Sardinha, Maria Emilia Zenteno, Yolanda Calle, Jacqueline F. Jacysyn, Daniel D. De Carvalho, Gustavo P. Amarante-Mendes, Maria Aparecida Zanichelli, Welbert Oliveira Pereira
Publikováno v:
Pereira, W O, De Carvalho, D D, Zenteno, M E, Ribeiro, B F, Jacysyn, J F, Sardinha, L R, Zanichelli, M A, Hamerschlak, N, Pagnano, K B, Jones, G E, Castro, F A, Amarante-Mendes, G P & Calle, Y 2017, ' BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy ', Cell Death & Disease, vol. 8, no. 10, pp. e3114 . https://doi.org/10.1038/cddis.2017.458
Cell Death & Disease
Cell Death & Disease
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the BCR–ABL1 tyrosine kinase (TK). The development of TK inhibitors (TKIs) revolutionized the treatment of CML patients. However, TKIs are not effective to those at advanced p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::000b2b709b907f61aa002affee8a544e
https://kclpure.kcl.ac.uk/ws/files/80348220/Pereira_et_al_Cell_Death_Disease_2017.pdf
https://kclpure.kcl.ac.uk/ws/files/80348220/Pereira_et_al_Cell_Death_Disease_2017.pdf
Publikováno v:
Nature biotechnology
Epigenetic modifications work in concert with genetic mechanisms to regulate transcriptional activity in normal tissues and are often dysregulated in disease. Although they are somatically heritable, modifications of DNA and histones are also reversi
Publikováno v:
Scopus-Elsevier
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exerts a cancer cell-specific pro-apoptotic activity. This property made the TRAIL associated pathway one of the most promising strategies aimed at inducing tumor-selective death. In
Autor:
M A Zago, Jacqueline F. Jacysyn, Maria Aparecida Zanichelli, J M G Leroy, Renata Binato, Daniel D. De Carvalho, Eliana Abdelhay, Gustavo P. Amarante-Mendes, A. E. B. Bueno-da-Silva, Welbert Oliveira Pereira, R Proto-Siqueira, Fabíola Attié de Castro, M D Colassanti
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
Tumor necrosis factor-related apoptosis-inducing ligand-TNFSF10 (TRAIL), a member of the TNF-α family and a death receptor ligand, was shown to selectively kill tumor cells. Not surprisingly, TRAIL is downregulated in a variety of tumor cells, inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90304491907dfcd8b707a3ca84bcf73